In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

While the previous PATHFINDER study—a prospective, year-long examination of about 6,600 people—showed that Galleri could more ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

Philips is rolling out what it describes as a next-generation point-of-care ultrasound system, designed specifically for ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...